CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

The management of polycystic liver disease by tolvaptan

Tsuneo Takenaka, Soichiro Miura, Masaki Kitajima

Clin Mol Hepatol. 2020;26(1):70-73. Published online 2019 June 13 DOI: https://doi.org/10.3350/cmh.2019.0026

The management of polycystic liver disease by tolvaptan

Tsuneo Takenaka, Soichiro Miura, Masaki Kitajima

Clinical and Molecular Hepatology. 2020;26(1):70-73

Link1

Link2 Link3

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Ioannis Bellos

Therapeutics and Clinical Risk Management. 2021;Volume 17:649-656

Link1 Link2

Tolvaptan improves kidney health in polycystic kidney disease

Springer Healthcare News. 2012;1(1):

Link1

Link2 Link3

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

Hiroki Mizuno, Akinari Sekine, Tatsuya Suwabe, Daisuke Ikuma, Masayuki Yamanouchi, Eiko Hasegawa, Naoki Sawa, Yoshifumi Ubara, Junichi Hoshino

PLOS ONE. 2022;17(2):e0264065

Link1

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease

Inge A. Hoevenaren, Ruth Wester, Robert W. Schrier, Kim McFann, R. Brian Doctor, Joost P. H. Drenth, Gregory T. Everson

Liver International. 2007;28(2):264-270

Link1 Link2

Systematic review: the pathophysiology and management of polycystic liver disease

F. Temmerman, L. Missiaen, B. Bammens, W. Laleman, D. Cassiman, C. Verslype, J. van Pelt, F. Nevens

Alimentary Pharmacology & Therapeutics. 2011;34(7):702-713

Link1 Link2

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

Hannah A. Blair

Drugs. 2019;79(3):303-313

Link1 Link2

Link3

Commentary on: Tolvaptan in Patients With Autosomal-Dominant Polycystic Kidney Disease

Peter Black, Roger Sutton

Urology. 2013;81(4):705-706

Link1 Link2

Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease: Polycystic Liver Disease

Fouad T. Chebib, Marie C. Hogan

Polycystic Kidney Disease. 2018;171-195

Link1

Tolvaptan listed for polycystic kidney disease in Australia

PharmacoEconomics & Outcomes News. 2019;819(1):39-39

Link1

Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.